NCT02821416 - Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 11, 2016

Primary Completion Date

October 22, 2019

Study Completion Date

October 22, 2019

Conditions

Asthma

Interventions

BIOLOGICAL

Benralizumab

Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive

OTHER

Placebo

Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive

Trial Locations (6)

Research Site, Calgary

Research Site, Edmonton

Research Site, Vancouver

Research Site, Hamilton

Research Site, Québec

Research Site, Saskatoon